There are two types of glutamine: L-glutamine and D-glutamine. While they are very similar, they have slightly different molecular structures. Many foods contain abundant amounts of L-glutamine ...

We found that the amino acid glutamine is required to activate the mevalonate pathway. Glutamine starvation inhibited cholesterol synthesis and blocked transcription of the mevalonate pathway—even in ...

Actemra was a major contributor to this outperformance, as the company observed slower-than-anticipated erosion from biosimilars. “3Q sales are a small positive, but we largely see the ...

The growing portfolio of inflammatory and immune diseases and oncology biosimilars is a testament to the company's commitment to biosimilars Fresenius Kabi (CNW Group/Fresenius Kabi Canada Inc ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, and role of tocilizumab in rheumatoid arthritis (RA) are reviewed. Summary: Tocilizumab is a novel monoclonal antibody that ...

Actemra is widely used as a treatment for rheumatoid arthritis, but has seen a new lease of life as a COVID-19 treatment, with so much demand during the pandemic that it has outstripped supply.

Am J Health Syst Pharm. 2008;65(15):1413-1418. Anthony Sebba, M.D., is Assistant Clinical Professor, University of South Florida, 36338 U.S. Highway 19 North, Palm ...

Triple-negative breast cancer (TNBC) metabolism and cell growth uniquely rely on glutamine uptake by the transporter ASCT2. Despite previous data reporting cell growth inhibition after ASCT2 knockdown ...

The European Commission has approved the first biosimilar version of Actemra/RoActemra, Roche’s $3 billion blockbuster, from German drugmaker Fresenius Kabi. The biosimilar of IL-6 inhibitor ...

Objectives The efficacy of tocilizumab (TCZ), an anti-interleukin-6 receptor antibody, has not previously been evaluated in a population consisting exclusively of patients with early rheumatoid ...

Objectives To evaluate the efficacy and safety of first-line tocilizumab in PMR. Methods In a prospective open-label study (ClinicalTrials.gov: NCT01713842), 20 glucocorticoid-free patients fulfilling ...